Contrarius Investment Management, an investment management company, released its third-quarter investor letter for the ...

CRISPR Therapeutics AG (CRSP) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to ...

Shares of CRISPR Therapeutics CRSP closed at $40.97 on Tuesday, close to their 52-week low of $36.52. This decline in CRSP stock is mainly due to a lack of pipeline updates, which is not sitting well ...

CRISPR Therapeutics CRSP stock rose more than 25% in the past week, thanks to the encouraging fourth-quarter 2024 results and a rating upgrade by a Wall Street analyst. Alongside earnings results, ...

We came across a bullish thesis on CRISPR Therapeutics AG (CRSP) on wallstreetbets Subreddit Page by MADD-Scientis. In this article, we will summarize the bulls’ thesis on CRSP. CRISPR Therapeutics AG ...

Investors who witnessed Moderna’s (Nasdaq: MRNA) meteoric rise during the pandemic know just how profitable new biotechnology companies can be. As a pioneer in gene-editing medicines, CRISPR ...

CRISPR Therapeutics AG (NASDAQ:CRSP) is among the top 10 stocks to buy from Cathie Wood’s stock portfolio. CRISPR made up roughly 3.8% of ARK Investment’s disclosed equity portfolio at ...

Gene therapy stocks like CRISPR Therapeutics and Intellia Therapeutics are facing significant volatility in 2025, influenced by market instability and regulatory uncertainties. CRSP is better ...

In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $56.46, marking a -2.5% move from the previous day.